The evidence supports over-the-counter access to progestin-only pills: A research summary

Mar 16

HRA Pharma has submitted an application to the FDA for an over-the-counter (OTC) progestin-only birth control pill (POP). If approved, Opill would be the first OTC birth control pill available in the United States. This research summary highlights the safety and efficacy of POPs, experiences with and interest in using them, and the challenges and barriers to accessing birth control pills in the current prescription-only environment.

Read Fact Sheet

Last updated: April 1, 2024

barriersBIPOCcontraceptive usecontraindicationsinterestOTC accessprogestin-only pillssafety and efficacyunintended pregnancyUnited States

Free the Pill

The evidence supports over-the-counter access to progestin-only pills: A research summary

Letter from Free the Pill coalition to FDA Commissioner Dr. Robert M. Califf

A commentary on progestin-only pills (POPs) and the “three-hour window” guidelines: Timing of ingestion and mechanisms of action